CADL

Candel Therapeutics, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Form 8-K reports on the Annual Meeting of Stockholders held by Candel Therapeutics, Inc. on June 26, 2024. The record date for the meeting was May 15, 2024, with 29,756,005 outstanding shares of voting common stock.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.

Material Changes and Voting Results

Stockholders voted on two primary proposals:

• Proposal 1 (Director Election): Stockholders elected three Class III directors to serve until the 2027 annual meeting: Nicoletta Loggia, Ph.D., R.Ph.; Christopher Martell; and Diem Nguyen, Ph.D., M.B.A.
• Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.

Investor Verification Checklist

• Verify the terms of office for the newly elected directors (Class III, expiring 2027).
• Confirm the engagement of KPMG LLP for the fiscal year ending December 31, 2024.
• Review the Definitive Proxy Statement filed on May 30, 2024, for detailed biographies of directors and background on the auditor appointment.
• Note the significant number of broker non-votes (7,427,258) on director elections, indicating shares held by brokers that were not voted on these matters.